BIOMAT Database Logo BIOMAT Database Logo

In vitro and in vivo effects of anti-tumor antibody covalently coupled to a chemotactic peptide. 1983

A L Sandberg, and R Obrist, and S E Mergenhagen

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D008114 Liver Neoplasms, Experimental Experimentally induced tumors of the LIVER. Hepatoma, Experimental,Hepatoma, Morris,Hepatoma, Novikoff,Experimental Hepatoma,Experimental Hepatomas,Experimental Liver Neoplasms,Hepatomas, Experimental,Neoplasms, Experimental Liver,Experimental Liver Neoplasm,Liver Neoplasm, Experimental,Morris Hepatoma,Novikoff Hepatoma
D008264 Macrophages The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.) Bone Marrow-Derived Macrophages,Monocyte-Derived Macrophages,Macrophage,Macrophages, Monocyte-Derived,Bone Marrow Derived Macrophages,Bone Marrow-Derived Macrophage,Macrophage, Bone Marrow-Derived,Macrophage, Monocyte-Derived,Macrophages, Bone Marrow-Derived,Macrophages, Monocyte Derived,Monocyte Derived Macrophages,Monocyte-Derived Macrophage
D008297 Male Males
D009239 N-Formylmethionine Effective in the initiation of protein synthesis. The initiating methionine residue enters the ribosome as N-formylmethionyl tRNA. This process occurs in Escherichia coli and other bacteria as well as in the mitochondria of eucaryotic cells. N Formylmethionine,Formylmethionine, N
D009240 N-Formylmethionine Leucyl-Phenylalanine A formylated tripeptide originally isolated from bacterial filtrates that is positively chemotactic to polymorphonuclear leucocytes, and causes them to release lysosomal enzymes and become metabolically activated. F-Met-Leu-Phe,N-Formyl-Methionyl-Leucyl-Phenylalanine,Formylmet-Leu-Phe,Formylmethionyl Peptide,Formylmethionyl-Leucyl-Phenylalanine,Formylmethionylleucylphenylalanine,N-Formylated Peptide,N-formylmethionyl-leucyl-phenylalanine,fMet-Leu-Phe,F Met Leu Phe,Formylmet Leu Phe,Formylmethionyl Leucyl Phenylalanine,Leucyl-Phenylalanine, N-Formylmethionine,N Formyl Methionyl Leucyl Phenylalanine,N Formylated Peptide,N Formylmethionine Leucyl Phenylalanine,N formylmethionyl leucyl phenylalanine,Peptide, Formylmethionyl,Peptide, N-Formylated,fMet Leu Phe
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D002630 Chemotactic Factors Chemical substances that attract or repel cells. The concept denotes especially those factors released as a result of tissue injury, microbial invasion, or immunologic activity, that attract LEUKOCYTES; MACROPHAGES; or other cells to the site of infection or insult. Chemoattractant,Chemotactic Factor,Chemotaxin,Chemotaxins,Cytotaxinogens,Cytotaxins,Macrophage Chemotactic Factor,Chemoattractants,Chemotactic Factors, Macrophage,Macrophage Chemotactic Factors,Chemotactic Factor, Macrophage,Factor, Chemotactic,Factor, Macrophage Chemotactic
D002633 Chemotaxis The movement of cells or organisms toward or away from a substance in response to its concentration gradient. Haptotaxis

Related Publications

A L Sandberg, and R Obrist, and S E Mergenhagen
Characterization of antibody covalently coupled to liposomes.
May 1982, Biochimica et biophysica acta,
A L Sandberg, and R Obrist, and S E Mergenhagen
A Novel Anti-HER2 Bispecific Antibody With Potent Tumor Inhibitory Effects In Vitro and In Vivo.
January 2020, Frontiers in immunology,
A L Sandberg, and R Obrist, and S E Mergenhagen
In vivo and in vitro anti-tumor effect of 14F7 monoclonal antibody.
December 2002, Hybridoma and hybridomics,
A L Sandberg, and R Obrist, and S E Mergenhagen
Monoclonal antibody covalently coupled with fatty acid. A reagent for in vitro liposome targeting.
September 1980, The Journal of biological chemistry,
A L Sandberg, and R Obrist, and S E Mergenhagen
Anti-bilirubin monoclonal antibody. I. Preparation and properties of monoclonal antibodies to covalently coupled bilirubin-albumin.
November 1988, Biochimica et biophysica acta,
A L Sandberg, and R Obrist, and S E Mergenhagen
In vivo and in vitro anti-tumor effects of fungal extracts.
February 2014, Molecules (Basel, Switzerland),
A L Sandberg, and R Obrist, and S E Mergenhagen
In vitro and in vivo anti-tumor effects of Astragalus membranaceus.
July 2007, Cancer letters,
A L Sandberg, and R Obrist, and S E Mergenhagen
Monoclonal antibody covalently coupled to liposomes: specific targeting to cells.
January 1981, Journal of supramolecular structure and cellular biochemistry,
A L Sandberg, and R Obrist, and S E Mergenhagen
In vitro and in vivo production of chemotactic inhibitors by tumor cells.
March 1979, The American journal of pathology,
A L Sandberg, and R Obrist, and S E Mergenhagen
Anti-Toxoplasma gondii Effects of a Novel Spider Peptide XYP1 In Vitro and In Vivo.
August 2021, Biomedicines,
Copied contents to your clipboard!